– Deerfield Management Company announced the closing of the Deerfield Healthcare Innovations Fund III, raising over $600 million.
– The fund focuses on advancing healthcare through investments in: Promising therapeutics, Innovative care delivery models, Emerging technologies, including machine learning and artificial intelligence.
– James Flynn, Managing Partner, stated the current environment is ideal for investing in life sciences, medtech, and healthcare services, with tech and data transforming health outcomes.
– The fund is supported by 29 leading research institutions and 9 industry partners, with innovation driven by Deerfield’s in-house ecosystem.
– Specialized teams like Deerfield Discovery and Development (3DC) and Deerfield Intelligence identify and advance promising solutions.
– Deerfield-founded entities such as Deerfield Catalyst and Genscience collaborate on product and service development.
– Headquarters located at Cure, a 12-story healthcare innovation campus in NYC offering research labs, meeting spaces, and business support.
– A portion of the fund’s profits will be donated to the Deerfield Foundation, a non-profit improving child health globally.
– Since 2005, the foundation has supported health initiatives from the South Bronx to Nepal, funded by employee contributions and fund profits.
– With over 30 years of experience and more than 180 professionals, Deerfield brings expertise across: Clinical/translational medicine, Drug/medical device development, Healthcare policy and markets, Machine learning and data science, Biostatistics and value-based care, and Corporate strategy and market access.
